A first patient has been dosed in IMAC Holdings’ Phase 1 clinical trial evaluating its investigational umbilical cord-derived mesenchymal stem cells (MSCs) as a potential treatment for bradykinesia, a common motor symptom of Parkinson’s disease.

The infusion treatment was given on Dec. 292020, by the trial’s lead investigator Ricardo Knight, MD, at IMAC’s facility in Brentwood, Tennessee, the company announced.